Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia
| Autor: | Tomoki Naoe, Koji Kato, Chika Nozaki, Hiroshi Mori, Seiji Kojima, Hitoshi Kiyoi, Takashi Kawabe, Takaharu Matuyama, Yoshiyuki Takahashi, Yoshiko Miyashita, Minoru Fukuda, Shinji Hasegawa, Keizo Horibe |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Oncogene Proteins Fusion Transcription Genetic Chromosomal translocation Gastroenterology Polymerase Chain Reaction Disease-Free Survival Fusion gene Immunophenotyping Japan hemic and lymphatic diseases Internal medicine White blood cell Acute lymphocytic leukemia medicine Humans Child neoplasms Survival rate Retrospective Studies business.industry Infant Retrospective cohort study Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Prognosis Neoplasm Proteins Survival Rate medicine.anatomical_structure Oncology Fusion transcript Child Preschool Pediatrics Perinatology and Child Health Immunology Core Binding Factor Alpha 2 Subunit Female Neprilysin business |
| Zdroj: | Journal of pediatric hematology/oncology. 20(3) |
| ISSN: | 1077-4114 |
| Popis: | A retrospective study was conducted to investigate the prognostic significance of TEL/AML1 fusion resulting from a cryptic t(12;21) in Japanese patients with childhood B-precursor acute lymphoblastic leukemia (ALL).Leukemic samples from 144 children with newly diagnosed ALL (104 with CD10-positive B-precursor ALL, 11 with CD10-negative B-precursor ALL, 5 with B-ALL, and 24 with T-ALL) were analyzed by reverse-transcription polymerase chain reaction.The frequency of patients with TEL/AML1 was 16% (23 of 144) and all patients with TEL/AML1 also had CD10-positive B-precursor ALL. TEL/AML1 was not found in any samples from the patients with T-ALL, B-ALL, or CD10-negative B-precursor ALL. Among patients with CD10-positive B-precursor ALL, age, initial white blood cell count, and immunophenotype did not differ with TEL/AML1 positivity, although the patients were predominantly male (p0.01). Clinical outcomes of 94 patients treated with recent protocols were analyzed. Five of the 21 (23.8%) patients with TEL/AML1 relapsed and 4 of these relapsed24 months after diagnosis. Although the overall 5-year survival rate was better among patients with TEL/AML1 fusion transcript than among those without it (87.3 +/- 8.7% versus 75.9 +/- 5.8%, respectively), the 5-year disease-free survival (DFS) rates of patients with TEL/AML1 fusion transcript and those without it were similar (64.0 +/- 13.5% versus 69.1 +/- 6.3%, respectively). However, for 57 patients treated with the latest intensive protocol, the 4-year DFS rate was much higher for the patients with TEL/AML1 fusion transcript than for those without it (100.0% v.s. 69.6 +/- 8.4%, respectively, p = 0.1472).This study confirmed that TEL/AML1 gene fusion is the most common genetic event in pediatric ALL in Japan and is restricted to CD10-positive B-precursor ALL. Moreover, it was associated with an improved survival rate among patients treated with intensive therapy. Therefore, these data suggest that the patients with TEL/AML1 may not necessarily be candidates for less aggressive treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|